Abstract:Objective: To identify the factors associated with long-term survival and guide the decision for primary surgery in patients with advanced high-grade serous ovarian cancer(HGSOC). Methods: In this case-control study, clinical parameters, including surgical and non-surgical associated factors, were collected and compared between the patients with short-term (<2 years) and long-term (>5 years) survival who all underwent primary debulking surgery (PDS) followed by carboplatin and paclitaxel chemotherapy from January 2004 to December 2016. Univariate analysis was examined by chi-square test and multivariate analysis was performed by logistic regression analysis. Results: There were 95 cases long-term survival (LTS group) and 77 cases short-term survival (STS group) in 698 newly diagnosed HGSOC patients with International Federation of Gynecology and Obstetrics (FIGO) stage Ⅲc and Ⅳ who met include and exclude criteria. (1) Univariate analysis showed that the proportion of complete cytoreduction with no visible residual disease (R0) at PDS and platinum sensitivity in LTS group were significantly higher than those in STS group (P<0.01). The surgical complexity score (SCS), the preoperative serum CA125 level and the ascites volume in the LTS group were significantly lower than those of the STS group (all P<0.05). In the LTS group, the preoperative incidence of lesions in retrograde peritoneum of the bladder, serosal and mesangial membrane of the small intestine, upper abdominal peritoneum and liver parenchyma were significantly lower than those in the STS group (all P<0.05). Multivariate logistic regression analysis showed that platinum sensitivity (OR=0.016, 95%CI: 0.004-0.063, P<0.01), ascites volume >500 ml (OR=3.193, 95%CI: 1.285-7.930, P=0.012), and SCS ≥8 (OR=17.433, 95%CI: 2.281-133.25, P=0.003) were independent factors affecting long-term survival (P>0.05). (2) Totally 37 of 95 in long-term survival and 16 of 77 in short-term survival achieved R0 cytoreduction at PDS. Univariate analysis showed that preoperative serum CA125 level, preoperative lesion score, preoperative lesion (DS) score, ascites volume, platinum sensitivity,and SCS were significantly correlated with the R0 PDS (all P<0.05). Multivariate analysis showed that ascites volume >500 ml (OR=5.199, 95%CI: 2.015-13.409, P=0.001), DS >2 (OR=15.264, 95%CI: 5.843-39.874, P<0.01) and SCS ≥4 (OR=4.176, 95%CI: 1.618-10.777, P=0.003) were independent factors associated with R0 cytoreduction. In patients with DS ≤2 or SCS <4, but not those with DS >2 or SCS ≥4, R0 cytoreduction was significantly associated with long-term survival. Conclusion: The intrinsic biology of tumor is the factor influencing long-term survival of advanced HGSOC patients, and those who present with wide intraperitoneal metastases and need to remove multiple organs may not benefit from R0 cytoreduction.

Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer

Salvage Cytoreductive Surgery for Patients with Recurrent Endometrial Cancer: A Retrospective Study

Non-exenterative surgical management of recurrent endometrial carcinoma

Salvage Surgery in Recurrent Oral Squamous Cell Carcinoma

Prognostic factors of patients with recurrent uterine malignancies undergoing secondary cytoreductive surgery

Oncological outcome of surgical management in patients with recurrent uterine cancer-a multicenter retrospective cohort study-CEEGOG EX01 Trial

Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift

How to Increase the Optimal Rate of Secondary Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

Recurrence Patterns and Outcomes of Salvage Surgery in Cases of Non-Curative Endoscopic Submucosal Dissection without Additional Radical Surgery for Early Gastric Cancer

Effect of Cytoreductive Surgery on Survival of Patients with Recurrent Epithelial Ovarian Cancer

2022-RA-276-ESGO Value of Surgical Cytoreduction for Subsequent Ovarian Cancer Relapse in Patients Previously Treated with Chemotherapy Alone at 1St-Relapse: a Subanalysis of the DESKTOP III/ENGOT-ov20 Trial

Survival Dynamics in Advanced Ovarian Cancer: R2 Resection Versus No-Surgery Paths Explored

Impact of Salvage Surgery Following Colonic Endoscopic Polypectomy for Patients with Invasive Neoplasia.

Salvage surgery for patients with residual/persistent diseases after improper or insufficient treatment of oral squamous cell carcinoma: can we rectify these mistakes?

Effectiveness of adjuvant systemic therapy following complete cytoreductive surgery in patients with recurrent granulosa cell tumours of the ovary

Surgery and Salvage Chemotherapy for Chinese Women with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Case-Control Study

Salvage Surgery for Esophageal Cancer: How to Improve Outcomes?

Prognostic Factors and Role of Salvage Surgery in Chemorefractory Ovarian Germ Cell Malignancies: a Study in Chinese Patients.

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort